



ESMO Advanced Course on Early Stage Non-Small-Cell Lung Cancer

PROGRAMME

**ESMO
ADVANCED COURSE**

**ATHENS GREECE
29-30 APRIL 2025**

CO-CHAIRS

Helena Linardou, Greece

Giannis Mountzios, Greece

Solange Peters, Switzerland

esmo.org

ESMO ADVANCED COURSE PROGRAMME EARLY STAGE NON-SMALL-CELL LUNG CANCER

Prevention, screening, diagnosis, multidisciplinary management
and therapeutic advances

Athens, Greece
29-30 April 2025

CO-CHAIRS Helena Linardou, Greece
Giannis Mountzios, Greece
Solange Peters, Switzerland

SPEAKERS Anne-Marie Dingemans, Netherlands
Lizza Hendriks, Netherlands
Keith Kerr, United Kingdom
Jarushka Naidoo, Ireland
Noemi Reguart, Spain
Jordi Remon, France
Suresh Senan, Netherlands
Egbert Smit, Netherlands
Paul Van Schil, Belgium

LEARNING OBJECTIVES

- To familiarise with prevention, smoking cessation and early diagnosis strategies in lung cancer
- To understand the current landscape of multimodality treatment options for stage I-III NSCLC including perioperative systemic treatments
- To recognise and validate the critical role of the multidisciplinary tumour board for the optimal care of patients with resectable NSCLC
- To discuss challenges in individualised approaches, including patient selection, biomarker evaluation and future clinical research direction

ACCREDITATION

The programme of this event has been accredited with **10 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This educational programme has been supported by



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano, Switzerland
Email: courses@esmo.org
www.esmo.org



Tuesday, 29 April 2025

- 09:00-09:15**
15' **Welcome and introduction**
Helena Linardou, GR and Giannis Mountzios, GR
- 09:15-10:35**
Session 1 - Prevention, screening and diagnosis
Chair: Helena Linardou, GR
- 20' Environmental carcinogens and lung cancer: Road to prevention
Giannis Mountzios, GR
- 20' Recommendations for implementing lung cancer screening
Lizza Hendriks, NL
- 20' State of the art in lung cancer pathology
Keith Kerr, UK
- 20' Discussion
- 10:35-11:05**
Coffee break
- 11:05-12:25**
Session 2 - Defining early stage NSCLC
Chair: Giannis Mountzios, GR
- 20' Clinical implications of the TNM classification evolution
Egbert Smit, NL
- 20' Defining resectability in early stage NSCLC
Paul Van Schil, BE
- 20' The evolving role of radiotherapy in early stage NSCLC
Suresh Senan, NL
- 20' Discussion
- 12:25-13:25**
Lunch
- 13:25-14:45**
Session 3 - Implementation of systemic treatments in resectable NSCLC
Chair: Helena Linardou, GR
- 20' Perioperative IO strategies
Giannis Mountzios, GR
- 20' Perioperative targeted agents in oncogene-addicted NSCLC
Noemi Reguart, ES
- 20' Methodology and available data evaluating ctDNA and MRD in early stage NSCLC
Keith Kerr, UK
- 20' Discussion
- 14:45-15:15**
Coffee break
- 15:15-16:55**
Session 4 - Challenges in multidisciplinary management of early stage NSCLC
Chair: Solange Peters, CH
- 20' The role of immunotherapy in inoperable stage III
Jordi Remon, FR

- 20' The challenge of IO pre-exposure for treatment strategies at metastatic relapse: State of the art and interrogations
Helena Linardou, GR
- 20' Using IO and RT: Prospects and clinical trials, including SRS and new strategies
Lizza Hendriks, NL
- 20' Toxicity and quality of life considerations for the implementation of IO in early stage NSCLC across strategies
Jarushka Naidoo, IE
- 20' Discussion
- 19:30 *Networking dinner***

Wednesday, 30 April 2025

09:00-10:20 **Session 5 - Optimising patient selection and future strategies** **Chair: Giannis Mountzios, GR**

- 20' Reconciliating evidence and decisions in patients exposed to perioperative chemo-immunotherapy and characterised by pathological or molecular responses
Solange Peters, CH
- 20' Ensuring equity and diversity in clinical trials of lung cancer
Helena Linardou, GR
- 20' Designing clinical trials for early stage NSCLC: The next steps
Anne-Marie Dingemans, NL
- 20' Discussion

10:20-10:50 *Coffee Break*

10:50-12:50 **Workshop sessions**

Two parallel workshop sessions with 30 delegates in each group (delegates will attend both sessions on a rotation basis)

- 15' Introduction based on clinical cases presented by speakers
- 40' Discussion
- 5' Break

Workshop 1
60' Multidisciplinary tumour board: Live discussion based on real cases
Jarushka Naidoo, IE, Jordi Remon, FR and Suresh Senan, NL (presenters of a clinical case)
Solange Peters, CH and Paul Van Schil, BE

Workshop 2
60' How do I select patients for perioperative strategies: The role of biomarkers
Anne-Marie Dingemans, NL, Helena Linardou, GR and Giannis Mountzios, GR (presenters of a clinical case)
Keith Kerr, UK and Egbert Smit, NL

12:50-13:10 **Feedback on the workshops from each group**

13:10-13:20 **Synthesis and wrap-up**
Helena Linardou, GR, Giannis Mountzios, GR and Solange Peters, CH

13:20-14:20 *Lunch*